HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Sturman Succeeds Lil' Drug Store's DeWolf As CHPA Board Chair

This article was originally published in The Tan Sheet

Executive Summary

Pfizer Consumer Healthcare President and General Manager Paul Sturman takes the reins as chairman of the Consumer Healthcare Products Association's board, announced outgoing chairman Chris DeWolf, president and CEO of Lil' Drug Store.

You may also be interested in...



CHPA Targets Policymakers With OTC Campaign To Undo “Negative Momentum”

The Consumer Healthcare Products Association aims at policymakers and thought leaders with a campaign to reverse the "negative momentum" that threatens the OTC industry with "death by a 1,000 cuts," President and CEO Scott Melville says.

Incoming CHPA Head Melville Brings Pharma Resume To OTC Learning Curve

The Consumer Healthcare Products Association's next president, Scott Melville, says his Rx manufacturing and distribution experience provides a foundation for "navigating a complex regulatory structure" in his first position on the OTC side of the drug industry.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel